Medical emergency?Emergency? Call 911. Nearest emergency roomsNearest ERs

Prescription medicine · generic available

Flutamide

Drug class: Androgen Receptor Inhibitor

The FDA’s “Established Pharmacologic Class”: the group of medicines that work in a similar way.

Official FDA data, not advice

Everything here comes from the U.S. Food and Drug Administration (FDA): the drug label, the NDC Directory, Drugs@FDA, recall reports and the drug shortage list. Each fact shows its source and date.

This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.

In an emergency, call 911. If someone may have taken too much of a medicine, call Poison Help: 1‑800‑222‑1222.

Quick answers

What is Flutamide used for?
The FDA-approved label (Eulexin, Waylis Therapeutics LLC, February 4, 2025) says: “Eulexin ® capsules are indicated for use in combination with LHRH-agonists for the management of locally confined Stage B 2 -C and Stage D 2 metastatic carcinoma of the prostate. Stage B 2 -C Prostatic Carcinoma Treatment with Eulexin ® capsules and the goserelin acetate implant should start eight weeks prior to initiating radiation therapy and continue during radiation therapy. …” This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
Does Flutamide have a boxed warning?
Yes. The FDA label for Eulexin has a boxed warning, the FDA’s strongest warning. Read it on the full label and ask your pharmacist.
Is there a shortage of Flutamide?
No current shortage is listed by the FDA for the products of this medicine (FDA data from October 30, 2026).
Has Flutamide been recalled?
No recall linked to the products of this medicine appears in the FDA enforcement reports we use.
Who makes Flutamide?
1 company lists prescription products of Flutamide in the FDA NDC Directory, including Waylis Therapeutics LLC.

What Flutamide is used for

Quoted from the “Indications and Usage” section of the FDA-approved label.

Eulexin ® capsules are indicated for use in combination with LHRH-agonists for the management of locally confined Stage B 2 -C and Stage D 2 metastatic carcinoma of the prostate. Stage B 2 -C Prostatic Carcinoma Treatment with Eulexin ® capsules and the goserelin acetate implant should start eight weeks prior to initiating radiation therapy and continue during radiation therapy. …

— FDA label: Eulexin, Waylis Therapeutics LLC, effective February 4, 2025. Read the full label on DailyMed →

The FDA has 2 labels for products of this medicine (different makers and forms); uses can differ between them. Check the label that comes with your own medicine.

This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.

Boxed warning

A boxed warning (“black box”) is the FDA’s strongest warning on a drug label, for serious or life-threatening risks.

This label has a boxed warning. Read it on the full label →

2 of 2 FDA labels for this medicine have a boxed warning.

Forms and how it is given

Dosage formsCapsule
RouteOral
Prescription products2 in the FDA NDC Directory
Brand namesEulexin

Companies that list this medicine

Labelers in the FDA NDC Directory: the company named on the package (maker or distributor), with the number of prescription products.

FDA approval history

  • ANDA: Abbreviated New Drug Application: how a generic version is approved.

Generic approvals (1)

Shortage status

The FDA drug shortage list does not show these products.

FDA Drug Shortages database →

Recalls

No recall linked to these products (by their NDC code) appears in the FDA enforcement reports.

Official identifiers

RxCUI (RxNorm)197726, 205646
SPL set ID of the quoted label0a905e25-42b6-4937-a689-f01a8f22e644
FDA labels (SPL)2
FDA applications1 ANDA
Active ingredients (FDA)FLUTAMIDE

Sources

  1. FDA-approved label on DailyMed (National Library of Medicine) — Eulexin, Waylis Therapeutics LLC, effective February 4, 2025; via openFDA, FDA data exported October 30, 2026, retrieved October 31, 2026
  2. NDC Directory (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
  3. Drugs@FDA (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
  4. Drug recall enforcement reports (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 27, 2026, retrieved October 31, 2026
  5. Drug shortages (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026

openFDA data is provided by the FDA as is; it may be incomplete. Always rely on the label that comes with your medicine. FDA Enforcement Report search →

Report an error → · Information for medicine makers